Resources Available for You
Find clear explanations of treatment options and a step-by-step treatment flow to assist you in making informed choices about your breast cancer care.
Resources for Early Breast Cancer
Treatment Flow Chart
Treatment Options for Early Breast Cancer
Treatment | Categories of Medication | Medication Name |
|---|---|---|
Hormonal therapy | Selective estrogen receptor modulator | • Tamoxifen • Toremifene |
Selective estrogen receptor degrader (SERD) | • Fulvestrant | |
Aromatase inhibitors | • Anastrozole • Exemestane • Letrozole | |
Targeted therapy for hormone receptor-positive | Cyclin-dependent kinase 4 and 6 inhibitors (CDK 4/6 inhibitors) | • Palbociclib • Ribociclib • Abemaciclib |
Mammalian target of rapamycin (mTOR) Inhibitors | • Everolimus | |
Anti-HER2 therapy | HER2 receptor antagonist | • Trastuzumab • Pertuzumab |
Pertuzumab: HER 2 receptor antagonist Trastuzumab: HER2 receptor antagonist Hyaluronidase-zzxf: Endoglycoside | Pertuzumab, trastuzumab and hyaluronidase-zzxf | |
HER2 antibody-drug conjugate | • Ado-trastuzumab entansine • Fam-trastuzumab deruxtecan | |
Tyrosine kinase inhibitors | • Tucatinib • Neratinib • Lapatinib | |
Chemotherapy | Anti-microtubule agents | • Paclitaxel • Docetaxel • Eribulin • Vinorelbine • Ixabepilone |
Anthracyclines | • Doxorubicin • Epirubicin • Liposomal doxorubicin | |
Alkylating agents | • Carboplatin • Cisplatin • Cyclophosphamide | |
Antimetabolites | • Capecitabine • Gemcitabine • Fluorouracil • Methotrexate | |
Immunotherapy | Programmed death-ligand 1 (PD-L1) inhibitor | • Atezolizumab • Pembrolizumab |
Targeted therapy for BRCA gene changes | Poly (ADP-ribose) polymerase (PARP) Inhibitors | • Olaparib • Talazoparib • Rucaparib • Veliparib • Niraparib |
